elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Cancer
Conditions
Hematologic Cancer
Trial Timeline
Aug 1, 2008 → Oct 1, 2016
NCT ID
NCT00742560About elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection is a phase 2 stage product being developed by AbbVie for Hematologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00742560. Target conditions include Hematologic Cancer.
What happened to similar drugs?
1 of 5 similar drugs in Hematologic Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00742560 | Phase 2 | Completed |
Competing Products
20 competing products in Hematologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 39 |
| RLYB116 for Injection | Rallybio | Phase 1 | 19 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 39 |
| Isavuconazole | Astellas Pharma | Phase 2 | 35 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 29 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 36 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 29 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 36 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 29 |
| ABBV-101 | AbbVie | Phase 1 | 36 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 29 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 36 |
| ridaforolimus | Merck | Phase 2 | 35 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 1 | 29 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 2 | 42 |
| ARQ 621 | Merck | Phase 1 | 29 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Pelabresib | Novartis | Phase 3 | 47 |